Alzheimer's Disease Research
Alzheimer's disease (AD), the most common type of dementia, is an irreversible and progressive neurodegenerative disorder causing cognitive and functional impairment. It is characterized by formation of protein aggregates and progressive loss of neurons in the central nervous system (CNS). The symptoms of AD include short-term memory loss, confusion, irritability, aggression and mood swings, progressing to long-term memory deficit, withdrawal from social interactions and subsequently a loss in higher central functioning.
Alzheimer's Disease Research Products Targets
- Others (23)
- Cyclooxygenase (24)
- Complement (2)
- AMPA Receptor (45)
- Nicotinic (α7) Receptor (25)
- Nicotinic (α4β2) Receptor (14)
- NMDA Receptor (87)
- Kainate Receptor (22)
- Microtubule (19)
- DYRK (3)
- Cholinesterase (10)
- Autophagy (44)
- Antioxidant (19)
- Amyloid beta Peptide (28)
- Estrogen and Related Receptor (33)
- Glycogen Synthase Kinase 3 (20)
- gamma-Secretase (9)
Products for Alzheimer's Disease Research - Page 29
- Cat.No. Product Name Information/Activity
-
BCC6151
CMPDA
CMPDA is a positive allosteric modulator of AMPA receptors with EC50s of 45.4 ± 4.2 nM/63.4 ± 5.6 nM for GluA2i/GluA2o receptor.
-
BCC7532
CX 546
CX546 is a selective positive AMPAR modulator; the prototypical ampakine agent.
-
BCC6759
Cyclothiazide
2259-96-3
-
BCC5951
PEPA
PEPA is an allosteric modulator of AMPA receptors; binds to the GluA2o and GluA3o LBDs and can be utilized as an indicator of AMPA receptor heterogeneity.
-
BCC6322
PF 4778574
PF-4778574 is a positive allosteric modulation of AMPA receptor with EC50 of 45 to 919 nM in differenct cells.
-
BCC6081
S 18986
S 18986 is a selective, orally active, brain penetrant positive allosteric modulator of AMPA-type receptors. S 18986 shows cognitive enhancing properties in rodents. S 18986 activates the release of noradrenaline and acetylcholine in rat hippocampus and enhances rat memory in object-recognition tests.
-
BCC4219
Aniracetam
Aniracetam(Ro 13-5057) is a nootropics and neuroprotective drug, which is selectively modulates the AMPA receptor and nAChR.
-
BCC6974
IDRA 21
22503-72-6
-
BCC5787
pep2-AVKI
1315378-69-8
-
BCC5786
pep2-EVKI
1315378-67-6


